Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ATIC | P31939 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629553 | 0.88 | PKM (0.56) | ALDH1A1PKMMAPT | |
| SCHEMBL13629414 | 0.88 | MAPT (0.55) | CYP19A1FFAR4ALDH1A1TDP1PKM | |
| SCHEMBL13852925 | 0.85 | PKM (0.75) | ALDH1A1TDP1PKMMAPTHIF1A | |
| SCHEMBL13629403 | 0.84 | CES1 (0.58) | CES1CYP19A1FFAR4ALDH1A1TDP1 | |
| SCHEMBL13629552 | 0.83 | PKM (0.74) | CYP19A1FFAR4ALDH1A1PKMMAPT | |
| SCHEMBL13629421 | 0.82 | BRD4 (0.56) | FFAR4MAPTHIF1AFFAR1 | |
| SCHEMBL13629329 | 0.82 | ALDH1A1 (0.65) | ALDH1A1TDP1MAPT | |
| SCHEMBL7181291 | 0.81 | CES1 (0.62) | CES1CYP19A1FFAR4ALDH1A1TDP1 | |
| SCHEMBL17174222 | 0.80 | CES1 (0.66) | CES1CYP19A1FFAR4ALDH1A1TDP1 | |
| SCHEMBL6553107 | 0.78 | UCHL1 (0.76) | CES1ALDH1A1TDP1MAPTPRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | CES1 3173/4885CYP19A1 3220/4885FFAR4 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.